To order any of the following, please contact one of the specialty pharmacies (SPs) or distributors listed below.
The recommended daily dose of 400 mg, in combination with azacitidine or decitabine, is supplied as 100-mg tablets.
100-mg bottle (28 ct): NDC # 0074-0576-30
100-mg bottle (qty 120): NDC # 0074-0576-22
The recommended daily dose of 600 mg, in combination with low-dose cytarabine, is supplied as 100-mg tablets.
100-mg bottle (qty 180): NDC # 0074-0576-34
10-mg and 50-mg wallets are available if dose holds should occur.
10-mg wallet (qty 14): NDC # 0074-0561-14
50-mg wallet (qty 7): NDC # 0074-0566-07
10-mg, 50-mg, and 100-mg unit doses are also available.
10-mg unit dose (qty 2): NDC # 0074-0561-11
50-mg unit dose (qty 1): NDC # 0074-0566-11
100-mg unit dose (qty 1): NDC # 0074-0576-11
The following network of SPs and distributors is authorized to dispense VENCLEXTA (venetoclax tablets). This network will assist providers and patients in obtaining VENCLEXTA. SPs may be able to provide services such as prior authorization assistance and identifying co-pay support options for eligible patients.
Biologics by McKesson
Phone: (800) 850-4306
Fax: (800) 823-4506
biologics.mckesson.com
Onco360 Oncology Pharmacy
Phone: (877) 662-6633
Fax: (877) 662-6355
onco360.com
Optum Specialty: FKA Avella and Diplomat
Phone: (877) 445-6874
Fax: (877) 342-4596
specialty.optumrx.com
ASD Healthcare
Phone: (800) 746-6273
Fax: (800) 547-9413
asdhealthcare.com
Cardinal Health Specialty Distribution
Phone: (855) 855-0708
Fax: (614) 553-6301
specialtyonline.cardinalhealth.com
McKesson Plasma and Biologics (MPB)
Phone: (877) 625-2566
Fax: (888) 752-7626
connect.mckesson.com
McKesson Specialty Health
Phone: (800) 482-6700
Fax: (800) 289-9285
mscs.mckesson.com
Oncology Supply
Phone: (800) 633-7555
Fax: (800) 248-8205
oncologysupply.com
Genentech and AbbVie do not influence or advocate the use of any one specialty distributor or specialty pharmacy. There is no representation or guarantee of service or coverage of any item.
US-VENA-220023
VENCLEXTA® and its design are registered trademarks of AbbVie Inc.
VENCLEXTA Prescribing Information.
VENCLEXTA Prescribing Information.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.2.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed June 14, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES® and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.2.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed June 14, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES® and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.
DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617-629.
DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617-629.
Data on file, AbbVie Inc. ABVRRTI71211.
Data on file, AbbVie Inc. ABVRRTI71211.
Data on file, AbbVie Inc. ABVRRTI71272.
Data on file, AbbVie Inc. ABVRRTI71272.
Data on file, AbbVie Inc. ABVRRTI67697.
Data on file, AbbVie Inc. ABVRRTI67697.
Data on file, AbbVie Inc. ABVRRTI71500.
Data on file, AbbVie Inc. ABVRRTI71500.
CRESEMBA Prescribing Information.
CRESEMBA Prescribing Information.
Drug development and drug interactions: table of substrates, inhibitors and inducers. US Food and Drug Administration website. https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm. Updated March 6, 2020. Accessed October 15, 2020.
Drug development and drug interactions: table of substrates, inhibitors and inducers. US Food and Drug Administration website. https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm. Updated March 6, 2020. Accessed October 15, 2020.
Perl AE. The role of targeted therapy in the management of patients with AML. Blood Adv. 2017;1(24):2281-2294.
Perl AE. The role of targeted therapy in the management of patients with AML. Blood Adv. 2017;1(24):2281-2294.
Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol. 1998;9(2):159-165.
Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol. 1998;9(2):159-165.
Mehta SV, Shukla SN, Vora HH. Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3. Neoplasma. 2013;60(6):666-675.
Mehta SV, Shukla SN, Vora HH. Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3. Neoplasma. 2013;60(6):666-675.
Tzifi F, Economopoulou C, Gourgiotis D, Ardavanis A, Papageorgiou S, Scorilas A. The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias. Adv Hematol. 2012;2012:524308.
Tzifi F, Economopoulou C, Gourgiotis D, Ardavanis A, Papageorgiou S, Scorilas A. The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias. Adv Hematol. 2012;2012:524308.
Banker DE, Groudine M, Norwood T, Appelbaum FR. Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. Blood. 1997;89(1):243-255.
Banker DE, Groudine M, Norwood T, Appelbaum FR. Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. Blood. 1997;89(1):243-255.
Data on file, Genentech Inc. 07/2022.
Data on file, Genentech Inc. 07/2022.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.